Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab and Pembrolizumab in Participants With Haematologic Malignancies
This study will evaluate the safety and efficacy of favezelimab (MK-4280) in combination with pembrolizumab (MK-3475) in participants with the following hematological malignancies: classical Hodgkin lymphoma (cHL) diffuse large B-cell lymphoma